- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06389292
A Pivotal Phase 3 Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia
April 26, 2024 updated by: Ascentage Pharma Group Inc.
An International, Multicenter, Randomized, Double-blind, Phase 3, Pivotal Registration Clinical Study of APG-2575 (Lisaftoclax) in Combination With Azacytidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
An international multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with azacitidine in newly diagnosed acute myeloid leukemia who are not eligible for standard induction chemotherapy.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The newly diagnosed acute myeloid leukemia, who are not eligible for standard induction chemotherapy, will be randomized to the investigational group (Lisaftoclax+ AZA) or the control group (placebo+ AZA).
Study Type
Interventional
Enrollment (Estimated)
486
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yifan Zhai, M.D., Ph.D.
- Phone Number: +86-20-28068501
- Email: yzhai@ascentage.com
Study Contact Backup
- Name: Lihui Liu, M.D.
- Email: Lihui.Liu@ascentage.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Hematology Hospital of the Chinese Academy of Medical Sciences
-
Contact:
- Hui Wei, M.D.
- Phone Number: 022-23909120
- Email: weihui@ihcams.ac.cn
-
Principal Investigator:
- Hui Wei, M.D.
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- Jie Jin, M.D.
- Email: jiej0503@163.com
-
Contact:
- Phone Number: 0571-87236896
-
Principal Investigator:
- Jie Jin, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients must have newly diagnosed AML that meets the criteria for acute myeloid leukemia (AML) and be ineligible for standard chemotherapy.
- Life expectancy of ≥3 months.
- Be able to accept oral administration.
- Patients aged ≥70 years with ECOG score of 0-2, or those aged≥18 years and <70 years with ECOG score of 0-3.
- Adequate kidney function.
- White blood cell ≤ 30×10^9/L.
- Adequate liver function.
- Men, women with childbearing potential, and their partners voluntarily use contraception that researchers consider effective.
- Be able to understand and voluntarily sign written informed consent.
- Patients must be willing and able to complete study procedures and follow-up examinations.
Exclusion Criteria:
- The patient was diagnosed with acute promyelocytic leukemia or AML (BCR-ABL1 positive.
- Active leukemic infiltration of the central nervous system.
- Active infection that requires systemic treatment.
- Use of a moderate or strong inducer and/or inhibitor of CYP3A4 within 7 days prior to first dose of the study drug.
- Previous treatment for hematologic disorders.
- Patients who has a cardiovascular disability status of New York Heart Association Class > 2.
- Patients have malabsorption syndrome or other conditions that cannot be administered through the gastrointestinal tract or affect drug absorption.
- Patients had a history of other malignancies prior to study initiation.
- Any other circumstances or conditions, at the discretion of the investigator, make the patient unsuitable to participate the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lisaftoclax (APG-2575) combined with Azacitidine
|
QD, oral administration, every 28 days for a dosing cycle.
QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.
|
Active Comparator: Placebo combined with Azacitidine
|
QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.
QD, oral administration, every 28 days for a dosing cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival(OS)
Time Frame: Up to 5 years
|
The primary endpoint was overall survival (OS), defined as the time from the date of randomization to the date of death of any cause.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Objective Response Rate (ORR)
Time Frame: Up to 5 years
|
ORR is defined as the proportion of patients who have achieved CR, CRi, CRh, MLFS or PR.
|
Up to 5 years
|
Safety evaluation based on the adverse event concurrence
Time Frame: Up to 5 years
|
Number of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) will be evaluated.
|
Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jianxiang Wang, M.D., Hematology Hospital of the Chinese Academy of Medical Sciences
- Principal Investigator: Jie Jin, M.D., Zhejiang University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
May 25, 2028
Study Completion (Estimated)
March 26, 2029
Study Registration Dates
First Submitted
April 24, 2024
First Submitted That Met QC Criteria
April 26, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 26, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APG2575AG301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on Lisaftoclax (APG-2575)
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RecruitingSolid Tumor | NeuroblastomaChina
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.Active, not recruitingChronic Lymphocytic Leukemia | Non Hodgkin LymphomaChina
-
Ascentage Pharma Group Inc.RecruitingT-Prolymphocytic LeukemiaUnited States
-
Ascentage Pharma Group Inc.RecruitingHematologic MalignanciesUnited States, Australia
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.Not yet recruiting
-
Ascentage Pharma Group Inc.RecruitingAML, AdultAustralia, United States
-
Ascentage Pharma Group Inc.CompletedPharmacokineticsChina
-
Ascentage Pharma Group Inc.RecruitingMultiple Myeloma | AmyloidosisUnited States
-
Ascentage Pharma Group Inc.RecruitingBreast Cancer | Solid Tumor, AdultUnited States
-
Ascentage Pharma Group Inc.Recruiting